A

ANI Pharmaceuticals

ANIP

63.840
USD
-1.87
(-2.85%)
Market Open
Volume
2,175
EPS
0
Div Yield
0
P/E
49
Market Cap
1,228,576,631
Related Instruments
A
ALGN
-3.810
(-1.64%)
228.270 USD
A
ANIX
0.04000
(1.20%)
3.37000 USD
C
CYH
-0.26000
(-4.94%)
5.00000 USD
G
GTHX
-0.11000
(-2.56%)
4.19000 USD
L
LCII
-6.170
(-5.28%)
110.590 USD
M
MIST
-0.05000
(-3.47%)
1.39000 USD
S
SGMO
-0.09690
(-12.11%)
0.70340 USD
S
SIEN
0
(0%)
0.000000 USD
V
VCEL
-2.900
(-5.72%)
47.800 USD
News

Title: ANI Pharmaceuticals

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.